Researching: GLP-1

Opinion: I'm a weight-loss doctor. Here's why I worry about GLP-1 'microdoses'

CHMP Diverges from FDA, Backs AZ’s Camizestrant and Novo’s Oral Wegovy

Lilly Extends Genetic Medicine Bet With $202M Engage Biologics Buy

Race intensifies to lead next wave of obesity drugs as trial results loom

ECO 2026: tirzepatide shows potential for T1D treatment

Novo, Lilly tout respective early response and weight loss maintenance data as GLP-1 rivalry intensifies

Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's

STAT+: FDA wants to exclude weight loss drugs from a compounding list

Lilly’s Foundayo Scores a Cardiovascular Win, Easing FDA Concerns Ahead of Diabetes Filing

STAT+: FDA eyes expanding testosterone therapy for libido